AHCO

AdaptHealth Corp.

Fundamental data last updated:June 4, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Devices

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

08/04/2026

Business Summary

AdaptHealth Corp., together with its subsidiaries, provides home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps to patients for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs. It serves beneficiaries of Medicare, Medicaid, and commercial insurance payors. AdaptHealth Corp. is headquartered in Plymouth Meeting, Pennsylvania.

 


Analyze AHCO on TradingView

VALUATION

P/E

-17.65

Market Cap ($M USD)

$1.41B

Forward P/E

6.72

PEG

0.02

PRICE TO SALES

0.49

PRICE TO BOOK

0.93

EV / EBITDA

7.01

5-Year Average P/E

Free Cash Flow Yield

13.63%

DCF Value

$32.27

Graham Number

N/A

Price to FCF

7.34

EV to FCF

17.51

Earnings Yield

-5.67%

FCF Yield

13.63%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$0.59

Next Year EPS Growth Estimate

$1.54

Next Year Revenue Growth Estimate

$628.86B

Return on Equity (ROE)

-5.11%

FREE CASH FLOW

Operating Margin

7.26%

Debt-to-Equity

1.25

Piotroski F-Score

5

Altman Z-Score

0.77

Return on Invested Capital (ROIC)

5.64%

Current Ratio

0.92

Quick Ratio

0.71

Net Debt to EBITDA

4.07

Interest Coverage

2.02

Gross Profit margin

5.38%

FCF PER SHARE

$1.41

REVENUE PER SHARE

$21.07

Analyze AHCO on TradingView

Gainseekers Quantitative Analysis

Summary

The market seems to be significantly undervaluing AHCO, as recent pricing indicated it traded well below its DCF value. The Forward P/E of 7.34 suggests optimism for future earnings, contrasting sharply with the negative current P/E. However, the Altman Z-score of 0.80 raises red flags about financial stability, hinting at potential distress. The negative earnings yield further underscores current profitability challenges, yet the market’s “Buy” consensus suggests faith in a turnaround.

AI Exposure / Tech Reliance

Operating in the Medical Devices industry, AHCO is well-positioned to leverage AI and tech advancements. The healthcare sector's increasing reliance on data-driven solutions could enhance operational efficiencies. This adaptability is crucial for maintaining competitiveness in a rapidly evolving landscape.

The Bull Case

For the discerning GARP investor, AHCO offers compelling value. With a robust ROIC of 5.64% and a strong FCF yield of 12.49%, the company demonstrates effective capital allocation and cash generation. The Piotroski F-Score of 5 indicates moderate financial health, while an operating margin of 7.26% suggests some pricing power. These metrics paint a picture of a company with potential for growth and efficient operations.

The Bear Case

Despite some strengths, AHCO faces significant structural risks. The negative EPS and a Return on Equity of -5.11% highlight profitability issues. The Altman Z-score suggests potential financial distress, and the current ratio below 1 indicates liquidity concerns. Additionally, the stock's proximity to its 52-week high could suggest technical overextension, posing a risk for new investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$14.40

Institutional Ownership %

1-Year Beta

1.57

Insider Buying % (6 Mo)

Distance to 52-Week High

29.76%

Distance to 52-Week Low

22.13%

EARNINGS SURPRISE %

-580.00%

50-DAY SMA

$11.67

200-DAY SMA

$10.16

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.